Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Golidocitinib Combined With Selinexor for the Treatment of Chronic Active Epstein-Barr Virus Disease (CAEBVD): A Multicenter, Prospective, Single-arm Clinical Study

NCT07369739 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.

NCT NCT07369739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07369739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Golidocitinib Combined With Selinexor for the Treatment of Chronic Active Epstein-Barr Virus Disease (CAEBVD): A Multicenter, Prospective, Single-arm Clinical Study
Lead sponsor
Beijing Friendship Hospital
Phase
Phase 2/3
Overall status
Recruiting
Start date
January 1, 2026
Completion date
January 1, 2028
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

caebv, ebv, lymphohistiocytosis